Literature DB >> 28894851

Translation and Validation of the Turkish Version of Lymphedema Quality of Life Tool (LYMQOL) in Patients with Breast Cancer Related Lymphedema.

Yeşim Bakar1, Alper Tuğral1, Özlem Özdemir1, Elif Duygu1, Ümmügül Üyetürk2.   

Abstract

OBJECTIVE: Breast cancer related lymphedema (BCRL) is a drastic situation that affects patients who have undergone breast cancer surgery. The impact of this condition on individuals' quality of life should be investigated in more detail to obtain better treatment results.
MATERIALS AND METHODS: In total, 65 patients with BCRL participated in this study. Nottingham Health Profile (NHP) was used to evaluate the validity of associated domains in Lymphedema Quality of Life Tool (LYMQoL). Both the LYMQoL and NHP were filled out by BCRL patients. To evaluate its test-retest reliability, the LYMQoL was subsequently performed seven days following its initial application. Measurement properties such as internal consistency, test-retest reliability, criterion validity and factor structure were tested. The internal consistency was assessed via Cronbach's alpha; test-retest reliability was assessed by the intra-class correlation coefficient (ICC).
RESULTS: Cronbach's alpha values ranged from 0.74 to 0.91 for the LYMQoL total and domain scores. Test-retest reliability was excellent (ICC=0.92-0.99). When the relation between LYMQoL and NHP was investigated, 'good' to 'very good' correlations were obtained (r=0.539-0.643, p<0.05) for all domains of LYMQoL. Exploratory factor analyses demonstrated a four-factor structure.
CONCLUSION: Turkish version of LYMQoL is a valid and reliable measurement tool to evaluate the quality of life in patients with BCRL.

Entities:  

Keywords:  Breast Cancer Related Lymphedema; Lymphedema Quality of Life Tool; Reliability; Turkish version; Validity

Year:  2017        PMID: 28894851      PMCID: PMC5544147          DOI: 10.5152/ejbh.2017.3522

Source DB:  PubMed          Journal:  Eur J Breast Health


  23 in total

1.  A comparison of two time intervals for test-retest reliability of health status instruments.

Authors:  Robert G Marx; Alia Menezes; Lois Horovitz; Edward C Jones; Russell F Warren
Journal:  J Clin Epidemiol       Date:  2003-08       Impact factor: 6.437

Review 2.  A systematic review of tools used to assess the quality of observational studies that examine incidence or prevalence and risk factors for diseases.

Authors:  Tatyana Shamliyan; Robert L Kane; Stacy Dickinson
Journal:  J Clin Epidemiol       Date:  2010-10       Impact factor: 6.437

Review 3.  Health-related quality of life with lymphoedema: a review of the literature.

Authors:  Philip A Morgan; Peter J Franks; Christine J Moffatt
Journal:  Int Wound J       Date:  2005-03       Impact factor: 3.315

4.  Breast cancer treatment-related lymphedema self-care: education, practices, symptoms, and quality of life.

Authors:  Sheila H Ridner; Mary S Dietrich; Nancy Kidd
Journal:  Support Care Cancer       Date:  2011-05       Impact factor: 3.603

5.  Psychosocial benefits of postmastectomy lymphedema therapy.

Authors:  B R Mirolo; I H Bunce; M Chapman; T Olsen; P Eliadis; J M Hennessy; L C Ward; L C Jones
Journal:  Cancer Nurs       Date:  1995-06       Impact factor: 2.592

Review 6.  Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.

Authors:  Tracey DiSipio; Sheree Rye; Beth Newman; Sandi Hayes
Journal:  Lancet Oncol       Date:  2013-03-27       Impact factor: 41.316

7.  Psychometric properties of the Breast Cancer and Lymphedema Symptom Experience Index: The Chinese version.

Authors:  Shuang Shi; Qian Lu; Mei R Fu; Qian Ouyang; Chao Liu; Jing Lv; Yingxin Wang
Journal:  Eur J Oncol Nurs       Date:  2015-06-09       Impact factor: 2.398

8.  Breast cancer-related lymphedema: women's experiences with an underestimated condition.

Authors:  Roanne Thomas-MacLean; Baukje Miedema; Sue R Tatemichi
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

9.  Upper limb lymphedema 27 (ULL27): Dutch translation and validation of an illness-specific health-related quality of life questionnaire for patients with upper limb lymphedema.

Authors:  P B Viehoff; F R van Genderen; H Wittink
Journal:  Lymphology       Date:  2008-09       Impact factor: 1.286

10.  The risk factors and prevalence of upper extremity impairments and an analysis of effects of lymphoedema and other impairments on the quality of life of breast cancer patients.

Authors:  S Kibar; M Dalyan Aras; S Ünsal Delialioğlu
Journal:  Eur J Cancer Care (Engl)       Date:  2016-01-13       Impact factor: 2.520

View more
  5 in total

1.  Psychometric performance of the Arabic versions of the Functional Assessment of Cancer Therapy-Breast plus Arm morbidity (FACT-B + 4) in patients with breast cancer related lymphedema: cross-sectional study.

Authors:  Hind Abdulaziz Al-Hoqail; Mohammed T A Omar; Maha Mohammed Al-Marwani; Einas Soliman Al-Eisa
Journal:  BMC Womens Health       Date:  2022-06-03       Impact factor: 2.742

2.  Examination of Sexual Quality of Life and Dyadic Adjustment among Women with Mastectomy.

Authors:  Sibel Telli; Aysel Gürkan
Journal:  Eur J Breast Health       Date:  2019-12-05

3.  Validity and reliability of the Turkish version of the lymphedema symptom intensity and distress survey.

Authors:  Zeynep Deveci; Özgül Karayurt; Buket Çelik; Sibel Eyigör
Journal:  Turk J Phys Med Rehabil       Date:  2021-12-01

Review 4.  Patient-Reported Outcome Measures in Lymphedema: A Systematic Review and COSMIN Analysis.

Authors:  Louise Marie Beelen; Anne-Margreet van Dishoeck; Elena Tsangaris; Michelle Coriddi; Joseph H Dayan; Andrea L Pusic; Anne Klassen; Dalibor Vasilic
Journal:  Ann Surg Oncol       Date:  2020-11-28       Impact factor: 5.344

Review 5.  Psychometric Properties of Quality of Life Questionnaires for Patients with Breast Cancer-Related Lymphedema: A Systematic Review.

Authors:  Estu Meilani; Asfarina Zanudin; Nor Azlin Mohd Nordin
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.